{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:17:41Z","timestamp":1788329861363,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["21K07203"],"award-info":[{"award-number":["21K07203"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["24K10414"],"award-info":[{"award-number":["24K10414"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01436-7","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:30:37Z","timestamp":1788323437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-8824","authenticated-orcid":false,"given":"Susumu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Uga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1436_CR1","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394424.","journal-title":"CA Cancer J Clin"},{"key":"1436_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","volume":"11","author":"A Barsouk","year":"2023","unstructured":"Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 2023;11:42.","journal-title":"Med Sci (Basel)"},{"key":"1436_CR3","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1436_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"1436_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, KEYNOTE-040 investigators, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367.","journal-title":"Lancet"},{"key":"1436_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41:790\u2013802.","journal-title":"J Clin Oncol"},{"key":"1436_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415434","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2415434.","journal-title":"N Engl J Med"},{"key":"1436_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Diaz LA Jr, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1436_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"1436_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00262-025-03993-6","volume":"74","author":"X Wang","year":"2025","unstructured":"Wang X, Li T, Slebos RJC, et al. Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunol Immunother. 2025;74:142.","journal-title":"Cancer Immunol Immunother"},{"key":"1436_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617335","volume":"11","author":"Y Lei","year":"2021","unstructured":"Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and challenges of predictive biomarkers for immune checkpoint blockade. Front Oncol. 2021;11:617335.","journal-title":"Front Oncol"},{"key":"1436_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.anndiagpath.2019.05.005","volume":"41","author":"S Kintsler","year":"2019","unstructured":"Kintsler S, Cassataro MA, Drosch M, Holenya P, Knuechel R, Braunschweig T. Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. Ann Diagn Pathol. 2019;41:24\u201337.","journal-title":"Ann Diagn Pathol"},{"key":"1436_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver EC, Cooper WA, Colebatch AJ, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141\u201356.","journal-title":"Pathology"},{"key":"1436_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","volume":"53","author":"T Takahara","year":"2021","unstructured":"Takahara T, Murase Y, Tsuzuki T. Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. Pathology. 2021;53:56\u201366.","journal-title":"Pathology"},{"key":"1436_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008339","volume":"12","author":"J Shen","year":"2024","unstructured":"Shen J, Choi YL, Lee T, et al. Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. J Immunother Cancer. 2024;12:e008339.","journal-title":"J Immunother Cancer"},{"key":"1436_CR16","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-22-1238","volume":"28","author":"HA Jung","year":"2022","unstructured":"Jung HA, Park KU, Cho S, et al. A phase II study of nivolumab plus gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma (KCSG HN17-11). Clin Cancer Res. 2022;28:4240\u20137.","journal-title":"Clin Cancer Res"},{"key":"1436_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842\u201359.","journal-title":"Cell Mol Immunol"},{"key":"1436_CR18","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"1436_CR19","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129:1212\u201324.","journal-title":"Br J Cancer"},{"key":"1436_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"1436_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41423-023-01013-0","volume":"20","author":"T Yoshimura","year":"2023","unstructured":"Yoshimura T, Li C, Wang Y, Matsukawa A. The chemokine monocyte chemoattractant protein-1\/CCL2 is a promoter of breast cancer metastasis. Cell Mol Immunol. 2023;20:714\u201338.","journal-title":"Cell Mol Immunol"},{"key":"1436_CR22","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ijc.23392","volume":"122","author":"Y Mizukami","year":"2008","unstructured":"Mizukami Y, Kono K, Kawaguchi Y, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008;122:2286\u201393.","journal-title":"Int J Cancer"},{"key":"1436_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000764","volume":"8","author":"LA Marshall","year":"2020","unstructured":"Marshall LA, Marubayashi S, Jorapur A, et al. Tumors establish resistance to immunotherapy by regulating treg recruitment via CCR4. J Immunother Cancer. 2020;8:e000764.","journal-title":"J Immunother Cancer"},{"key":"1436_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, LaPorte KM, Malek TR. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity. 2024;57:414\u201328.","journal-title":"Immunity"},{"key":"1436_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","volume":"50","author":"ED Tait Wojno","year":"2019","unstructured":"Tait Wojno ED, Hunter CA, Stumhofer JS. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity. 2019;50:851\u201370.","journal-title":"Immunity"},{"key":"1436_CR26","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/bjc.2017.336","volume":"117","author":"JM Vahl","year":"2017","unstructured":"Vahl JM, Friedrich J, Mittler S, et al. Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. Br J Cancer. 2017;117:1644\u201355.","journal-title":"Br J Cancer"},{"key":"1436_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712788","volume":"11","author":"C Idel","year":"2021","unstructured":"Idel C, Ribbat-Idel J, Klapper L, et al. Spatial distribution of immune cells in head and neck squamous cell carcinomas. Front Oncol. 2021;11:712788.","journal-title":"Front Oncol"},{"key":"1436_CR28","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.4049\/jimmunol.178.4.2278","volume":"178","author":"AV Gorbachev","year":"2007","unstructured":"Gorbachev AV, Kobayashi H, Kudo D, et al. CXC chemokine ligand 9\/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol. 2007;178:2278\u201386.","journal-title":"J Immunol"},{"key":"1436_CR29","first-page":"49","volume":"1","author":"P Tan","year":"2018","unstructured":"Tan P, Shi M, Lai L, et al. Regulative role of the CXCL13-CXCR5 axis in the tumor microenvironment. Precis Clin Med. 2018;1:49\u201356.","journal-title":"Precis Clin Med"},{"key":"1436_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/03946320241227312","volume":"38","author":"X Lin","year":"2024","unstructured":"Lin X, Zhao X, Chen Y, et al. CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma. Int J Immunopathol Pharmacol. 2024;38:3946320241227312.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1436_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029378","volume":"101","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Ma Y, Lv J, et al. Expression of chemokine CXCL8\/9\/10\/11\/13 and its prognostic significance in head and neck cancer. Medicine (Baltimore). 2022;101:e29378.","journal-title":"Medicine (Baltimore)"},{"key":"1436_CR32","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.4049\/jimmunol.2100341","volume":"208","author":"J Ren","year":"2022","unstructured":"Ren J, Lan T, Liu T, Wei XW, et al. CXCL13 as a novel immune checkpoint for regulatory B cells and its role in tumor metastasis. J Immunol. 2022;208:2425\u201335.","journal-title":"J Immunol"},{"key":"1436_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1189\/jlb.1009659","volume":"88","author":"LL Chan","year":"2010","unstructured":"Chan LL, Cheung BK, Li JC, Lau AS. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol. 2010;88:303\u201311.","journal-title":"J Leukoc Biol"},{"key":"1436_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70263","volume":"13","author":"S Tojo","year":"2024","unstructured":"Tojo S, Nakashiro KI, Kuribayashi N, Uchida D. Serum CXCL13 as a novel biomarker in oral squamous cell carcinoma. Cancer Med. 2024;13:e70263.","journal-title":"Cancer Med"},{"key":"1436_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093722","volume":"5","author":"BE Lippitz","year":"2016","unstructured":"Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5:e1093722.","journal-title":"Oncoimmunology"},{"key":"1436_CR36","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.3892\/or.2016.4765","volume":"35","author":"J Gao","year":"2016","unstructured":"Gao J, Zhao S, Halstensen TS. Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep. 2016;35:3265\u201374.","journal-title":"Oncol Rep"},{"key":"1436_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04268-5","volume":"12","author":"AE Herzog","year":"2021","unstructured":"Herzog AE, Warner KA, Zhang Z, et al. The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death Dis. 2021;12:988.","journal-title":"Cell Death Dis"},{"key":"1436_CR38","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/1535-7163.MCT-10-0258","volume":"9","author":"KJ Poth","year":"2010","unstructured":"Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther. 2010;9:2430\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1436_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cas.13433","volume":"109","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Fujieda K, Senju S, Ikeda T, Oshiumi H, Nishimura Y. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. Cancer Sci. 2018;109:523\u201330.","journal-title":"Cancer Sci"},{"key":"1436_CR40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632\u201342.","journal-title":"Cancer Immunol Res"},{"key":"1436_CR41","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3390\/cancers13153781","volume":"13","author":"J Siemert","year":"2021","unstructured":"Siemert J, Wald T, Kolb M, et al. Pre-therapeutic VEGF Level in plasma is a prognostic bio-marker in head and neck squamous cell carcinoma (HNSCC). Cancers (Basel). 2021;13:3781.","journal-title":"Cancers (Basel)"},{"key":"1436_CR42","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.7314\/APJCP.2014.15.7.3261","volume":"15","author":"VK Srivastava","year":"2014","unstructured":"Srivastava VK, Gara RK, Rastogi N, et al. Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev. 2014;15:3261\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1436_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3389\/fonc.2019.00656","volume":"9","author":"AT Kumar","year":"2019","unstructured":"Kumar AT, Knops A, Swendseid B, et al. Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis. Front Oncol. 2019;9:656.","journal-title":"Front Oncol"},{"key":"1436_CR44","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3390\/cells13201679","volume":"13","author":"A Plevriti","year":"2024","unstructured":"Plevriti A, Lamprou M, Mourkogianni E, et al. The role of soluble CD163 (sCD163) in human physiology and pathophysiology. Cells. 2024;13:1679.","journal-title":"Cells"},{"key":"1436_CR45","volume":"2","author":"R Chakrabarti","year":"2019","unstructured":"Chakrabarti R, Kapse B, Mukherjee G. Soluble immune checkpoint molecules: serum markers for cancer diagnosis and prognosis. Cancer Rep (Hoboken). 2019;2:e1160.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1436_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40364-024-00647-0","volume":"12","author":"L Chen","year":"2024","unstructured":"Chen L, Chao Y, Li W, Wu Z, Wang Q. Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications. Biomark Res. 2024;12:95.","journal-title":"Biomark Res"},{"key":"1436_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CJI.0000000000000408","volume":"45","author":"SL Lambert","year":"2022","unstructured":"Lambert SL, Zhang C, Guo C, et al. Association of baseline and pharmacodynamic biomarkers with outcomes in patients treated with the PD-1 inhibitor Budigalimab. J Immunother. 2022;45:167\u201379.","journal-title":"J Immunother"},{"key":"1436_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228770","volume":"21","author":"V Boschert","year":"2020","unstructured":"Boschert V, Teusch J, Aljasem A, et al. HGF-induced PD-L1 expression in head and neck cancer: preclinical and clinical findings. Int J Mol Sci. 2020;21:8770.","journal-title":"Int J Mol Sci"},{"key":"1436_CR49","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2147\/OTT.S242517","volume":"13","author":"T Lu","year":"2020","unstructured":"Lu T, Chen Y, Li J, et al. High soluble programmed death-ligand 1 predicts poor prognosis in patients with nasopharyngeal carcinoma. Onco Targets Ther. 2020;13:1757\u201365.","journal-title":"Onco Targets Ther"},{"key":"1436_CR50","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/cancers15061696","volume":"15","author":"P Clare","year":"2023","unstructured":"Clare P, Al-Fatyan F, Risheh B, Nellany K, Ward FJ, Abu-Eid R. A novel role for the soluble isoform of CTLA-4 in normal, dysplastic and neoplastic oral and oropharyngeal epithelia. Cancers (Basel). 2023;15:1696.","journal-title":"Cancers (Basel)"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01436-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:03:03Z","timestamp":1788328983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01436-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01436-7","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Susumu Suzuki received joint research funding from Sysmex Corporation. The other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Aichi Medical University (protocol code 2020-H033, 30 June 2020).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"133"}}